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Abstract 
BRM is an ATPase component of the SWI/SNF complex that regulates chromatin re-
modeling and cell proliferation and is considered a tumor suppressor. In this study we 
characterized transcripts from the Smarca2 gene that encodes the BRM protein. We found 
that the human Smarca2 gene (hSmarca2), like its mouse counterpart (mSmarca2), also 
initiated a short transcript from intron 27 of the long transcript. We name the long and 
short transcripts as Smarca2-a and Smarca2-b, respectively. Like its human counterpart, 
mSmarca2-a also underwent alternative splicing at the 54-bp exon 29. The hSmarca2-b 
had two alternative initiation sites and underwent alternative splicing at three different 
3’ sites of exon 1 and at exons 2, 3 and/or 5. We identified nine hSmarca2-b mRNA var-
iants that might produce five different proteins. mSmarca2-b also underwent alternative 
splicing at exon 3 and/or exon 5, besides alternatively retaining part of intron 1 in exon 1. 
Smarca2-b was expressed more abundantly than Smarca2-a in many cell lines and was 
more sensitive to serum starvation. Moreover, cyclin D1 also regulated the expression of 
both Smarca2-a and Smarca2-b in a complex manner. These data suggest that the func-
tions of the Smarca2 gene may be very complex, not just simply inhibiting cell prolifera-
tion, and in certain situations may be elicited mainly by expressing the much less known 
Smarca2-b, not the better studied Smarca2-a and its products BRM proteins. 
Key  words:  Alternative  splicing,  Tumor  suppressor  gene,  BRM,  Smarca2,  SWI/SNF  complex, 
Cancer, Cyclin D1 
Introduction 
Most  genes  in  a  eukaryotic  genome  consist  of 
exons and introns. During a splicing process, about 
91% of a transcript (pre-mRNA) sequence is removed 
as introns;  the  remaining 9% as exons are joined to 
form  a  mature  mRNA  for  protein  translation  (1). 
Transcripts from over 70% of the genes in the human 
genome undergo alternative splicing to produce dif-
ferent mature mRNAs  (2),  which greatly diversifies 
the protein products from individual genes. In a dis-
ease situation such as cancer that has gene mutations, 
even more alternative splicing events may occur be-
cause  over  14%  of  disease-causing  mutations  affect 
the splicing process (3,4), in part because the muta-
tions occur at splice sites, as in the case of the BRCA2 
Ivyspring  
International Publisher    Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
387 
gene (5).  
There  are  quite  a  few  patterns  of  alternative 
splicing, including cassette alternative exons, alterna-
tive 5’ splice sites, alternative 3’ splice sites, mutually 
exclusive splice sites and retained introns (1). More-
over,  one  gene  can  also  be  transcribed  to  different 
pre-mRNAs by using different promoters and initia-
tion sites, and each pre-mRNA may undergo several 
patterns of splicing, which together further increases 
the number of mature mRNAs from each individual 
gene.  A  well-studied  example  is  the  Drosophila 
Down  syndrome  cell  adhesion  molecule  (Dscam) 
gene, which can generate 38,016 mRNA variants by 
alternatively splicing its 95 exons (6). Another exam-
ple is the titin gene that is expressed to, on average, 
about 0.5 kg Titin protein in the muscle of an adult 
human (7). How the 363 exons of the human titin gene 
are alternatively spliced is still largely unknown but 
over one million splice variants are estimated (7). 
BRM is an ATPase component of the SWI/SNF 
complex  that  regulates  chromatin  remodeling.  It 
functions as a gatekeeper of proliferation in cancers 
(8) in part by its collaboration with the retinoblastoma 
(Rb) protein to repress E2F  (9). Most of  the known 
functions  of  BRM  protein  suggest  that  it  may  be  a 
tumor suppressor (10). However, BRM has also been 
shown  to  transactivate  the  telomerase  reverse  tran-
scriptase (Tert) gene and further modulate Tert splic-
ing  (11),  which  does  not  seem  to  support  its  tu-
mor-suppressive role because Tert activation is sup-
posed to promote cancer formation and progression. 
Possibly, the functions of BRM proteins may be com-
plex and may vary among different situations. 
Lost  or  decreased  expression  of  Smarca2,  the 
gene encoding the BRM proteins, has been reported in 
many cell lines of different types of cancer, which is in 
line  with  its  putative  role  as  a  tumor  suppressor 
(10,12-15). The gene silencing is generally considered 
to be due to epigenetic mechanisms (14,16), in part 
because there has not been any critical genetic change 
identified in those cell lines that have lost BRM ex-
pression,  although  loss  of  heterozygosity  in  the 
Smarca2-containing locus has been reported in some 
cancers (17). 
Like many other genes, Smarca2 may diversify 
its function by yielding multiple mRNA variants. In 
the NCBI database, the mouse Smarca2 (mSmarca2) 
gene  has  a  long  transcript  designated  herein  as 
mSmarca2-a and a short transcript coined herein as 
mSmarca2-b that is initiated from the intron 27 of the 
mSmarca2-a,  as  illustrated  in  figure  1.  The  human 
Smarca2 (hSmarca2) also has two mRNA variants but, 
unlike  the  mSmarca2  mRNA  variants,  they  are  de-
rived from alternative splicing at the exon 29, desig-
nated  herein  as  hSmarca2-a1  with  this  exon  and 
hSmarca2-a2 without this exon (Fig. 1). Reisman et al 
mentioned an additional transcription initiation site 
that is close to the one that initiates the Smarca2-a (10), 
but we are unable to illustrate it in figure 1 because it 
is unclear whether this initiation site is identified in 
the mouse, human or both species. 
In this communication, we report that the long 
transcript  in  the  mouse  also  undergoes  alternative 
splicing to generate mSmarca2-a1 that contains exon 
29, just like its human counterpart. On the other hand, 
the  hSmarca2  gene  also  initiates  a  short  transcript, 
hSmarca2-b, from two different sites in intron 27 of 
hSmarca2-a.  This  hSmarca2-b  undergoes  alternative 
splicing at three different 3’ sites of exon 1 and at ex-
ons  2, 3  and/or  5.  These  complex  patterns  of  tran-
scription  initiation and  alternative  splicing  may  en-
gender many different hSmarca2-b mRNA variants, 
and we identified nine of them. mSmarca2-b also had 
alternative splice variants. Moreover, Smarca2-a and 
Smarca2-b can be differentially expressed in different 
cell lines and regulated by cyclin D1 and by serum 
concentration. These findings suggest that the func-
tions of the Smarca2 gene may be very complex and 
may be elicited mainly by expressing the Smarca2-b in 
certain situations. 
Materials and Methods 
Cell lines and cell culture: 168FARN, 4T07, 4T1, 
66C14 and 67RN are cell lines established from the 
same  mouse  mammary  tumor  (18).  NMuMG  and 
HC11 are non-malignant mouse mammary epithelial 
cell  lines.  ND5  and  ND11  are  malignant  clones  of 
NMuMG cells transformed by cyclin D1 (19). MT-tgfα 
or T/M is a cell line established by us from a mam-
mary tumor developed in a female MT-tgfα transgenic 
or  MT-tgfα/MMTV-c-myc  double  transgenic  mouse, 
respectively. H5 and M8 are a pcDNA3.1-hygromycin 
empty  vector  and  a  pcDNA3.1-c-myc  expressing 
clone,  respectively,  of  an  Ela-myc  transgenic  mouse 
pancreatic  cancer  cell  line  (20,21).  MCF10A  is  a 
non-malignant  human  breast  epithelial  cell  line, 
whereas MCF7, MDA-MB231, T47D, and SKBR3 are 
human breast cancer cell lines. MCF15 is a new hu-
man  breast  cancer  cell  line  in  the  MCF  series  (22). 
GI101A and its parental GILMmix are human breast 
cancer  cell  lines  provided  by  Dr.  JE  Price  at  M.D. 
Anderson  Cancer  Center.  AsPC-1,  Panc-1,  Panc-28, 
L3.6pL and MiaCapa-2 are human pancreatic cancer 
cell lines. There were many more mouse and human 
cell lines that were used in this study but are not listed 
here because the related data are not presented. All 
the  cells  were  cultured  in  routine  conditions  with  Journal of Cancer 2011, 2 
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DMEM  containing  10%  serum.  The  cells  were  har-
vested when they reached about 80% confluence, but 
for  the  serum  starvation  study  the  medium  was 
changed to a new one without serum for additional 48 
hours of culture before cell harvest. 
Retroviral  infection:  A  human  cyclin  D1  (D1) 
cDNA or its K112E mutant (23) tagged with a Flag 
sequence at the N-terminus was inserted into a pMIG 
retroviral vector that contains an IRES-driven green 
fluorescent  protein  (GFP)  sequence  after  the  insert. 
These constructs and the empty vector were packaged 
in 293T cells and the resulting viruses were used to 
infect  desired  cells,  followed  by  sorting  for  GFP  to 
enrich the infected cells. 
RT-PCR  assay:  Total  RNA  samples  were  ex-
tracted from cells by using TRIzol (Invitrogen; catalog 
number: 15596-026), followed by DNase treatment to 
remove DNA. Mouse tissues were homogenized with 
polytron in a buffer containing protease K (24) before 
RNA  extraction  with  TRIzol.  RNA  samples  from 
normal  human  tissues  were  also  purchased  from 
Clontech  (www.clontech.com).  The  RNAs  were  re-
verse transcribed (RT) to cDNA using hexamer pri-
mers.  Amplification  by  Polymerase  chain  reaction 
(PCR) was conducted with the forward and reverse 
primers listed in table 1. 
Table 1: Primer list  
 
 
 
5’RACE  and  T-A  cloning:  Total  RNA  from 
L3.6pL  cells  was  used  for  a  5’RACE  assay  with 
FirstChoice  RLM-RACE  Kit  (Ambion,  Inc.  Austin, 
TX), following the manual. The hSmarca2R4230 (out-
er) and hSmarca2R4106 (inner) listed in table 1 were 
used  as  reverse  primers.  The  RACE  products  were 
fractionized in agarose gel, and dominant bands were 
purified  and  ligated  into  a  pGEM-T  Easy  Vector 
(Promega, Madison, WI). RT-PCR products were also 
cloned in this way. Bacterial clones transformed by 
the plasmids were selected and propagated. 
DNA  sequencing  and  sequence  analysis:  The 
desired band of PCR products in agarose gel was pu-
rified  with  a  DNA  purification  kit  from  UltraClean 
Gel DNA Extraction Kit (ISC BioExpress, Kaysville, 
UT), following the manual. The DNA sample was sent 
to Genewiz, Inc. (South Plainfield, NJ) for sequencing. 
Plasmid DNA of desired clones from T-A cloning or 
5’RACE was also sequenced. DNA sequence analysis 
was mainly conducted with DNAStar software. 
Western  blot  assay:  Cells  were  prepared  for 
protein  lysates  as  described  before  (25).  An  equal 
amount of proteins was fractioned in 12% SDS-PAGE 
and  then  transferred  onto  an  Immobilon-P  Nylon 
membrane  (Millipore,  Bedford,  MA).  After  being 
blocked with 5% milk, the membrane was incubated 
with a mouse monoclonal (catalog number: sc-166579) 
or a rabbit polyclonal (catalog number: sc-28710) BRM 
antibody  (Santa  Cruz  Biotech.,  Santa  Cruz,  CA)  at 
1:1000  dilution  and  then  with  a  corresponding  sec-
ondary antibody conjugated with a  horseradish pe-
roxidase, with three washes between each blocking. 
The  signal  was  visualized  by  luminal-based  chemi-
luminescent substrate (Pierce, Rockford, IL) on X-ray 
film (ISC BioExpress, Kaysville, UT).  
Results 
In this study we analyzed in a systematic man-
ner the transcription of mouse and human Smarca2 
gene and the splicing of the transcripts. Because the 
NCBI database documents a long and a short  tran-
scripts  of  Smarca2  in  the  mouse  but  only  the  long 
transcript in the human, we first determined the al-
ternative splicing of both transcripts in the mouse and 
then, based on the information from the mouse, ex-
plored  whether  the  short  transcript  was  also  ex-
pressed in the human and, if yes, whether it under-
went  alternative  splicing  as  well.  Once  the  mRNA 
variants were confirmed by sequencing, bioinformatic 
analyses were applied to determine their open read-
ing frames (ORF) and regulation of their expression 
by cyclin D1 and serum starvation was explored as 
the mechanistic part of the study. The results obtained 
were presented below in this logical order. 
Alternative splicing of mouse Smarca2-a 
Because in the NCBI database hSmarca2-a1 con-
tains the 54-bp exon 29 (Fig. 1A), we wonder whether 
this exon also appears in mSmarca2-a or mSmarca2-b.  Journal of Cancer 2011, 2 
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Using a forward primer at exon 26 (mSmarca2F3855; 
table 1) and a reverse primer (mSmarca2R4524) at the 
102-bp exon 31 of mSmarca2-a (the exon is numbered 
based on hSmarca2-a1), we performed PCR to amplify 
the RT products from many mouse tissues and cell 
lines. Results from some cell lines are presented in Fig. 
1B and 1C, whereas similar data obtained from many 
other cell lines or tissues are not shown. Purifying and 
then  sequencing  the  bottom  band  of  mSmarca2-a 
shown  in  Fig.  1B  revealed  that  it  was  the 
NM_011416.2  sequence  in  the  NCBI  database  that 
lacks  the  54-bp  exon  and  is  thus  designated  as 
mSmarca2-a2 (Fig. 1A). Sequencing the top band re-
vealed that it actually contained two cDNA sequenc-
es: one contains the 54-bp exon 29, like the hSmar-
ca2-a1  (Fig.  1A),  and is  thus  designated as  mSmar-
ca2-a1 (Supplementary Material: Fig. S1), whereas the 
other one is the mSmarca2-a2 lacking this exon. The 
mSmarca2-a1 was expressed more abundantly, rela-
tive to the mSmarca2-a2, manifested as higher peaks 
in the sequence graph (not shown).  
 
Fig 1: Expression of different Smarca2 mRNA variants. A: Illustration of human (h) and mouse (m) Smarca2 mRNA variants doc-
umented in the NCBI database, with access number (such as NM_003070.3) provided. Only several exons at the 3’-part for Smar-
ca2-a or the 5’-part for Smarca2-b are shown. Each box indicates an exon with the exon number inside. The figure below a box 
indicates the length of that exon in base-pairs (bp). Note that the two human Smarca2 variants differ by the alternative skip of the 
54-bp exon 29 and that the two mouse Smarca2 variants are denoted as –a2 or –b2 because they both lack the 54-bp exon, like the 
hSmarc2-a2. B: RT-PCR detection of mSmarca2 in H5 and M8 cells with F3855+R4524 primers for mSmarca2-a and F’43+R4524 
primers for Smarca2-b. As a negative control, the cDNA template was replaced with water. C: Expression of mSmarca2, detected by 
RT-PCR with the same primer sets as in (B), in a panel of mouse breast cancer or non-malignant cell lines (from lanes 1 to 9): 
168FARN, 4T07, 4T1, 66C14, 67RN, NMuMG, HC11, T/M and MT-tgfα. D & E: RT-PCR detection of mSmarca2-b in H5 and M8 cells, 
with the F’192 and R4524 primers, reveals two (D) or three bands (E) in agarose gel. F: Illustration of the three newly identified 
mSmarca2-b mRNA variants confirmed by sequence data, designated as mSmarca2-b3, -b4, and -b10, respectively. Note that all 
three variants differ from the mSmarca2-b2 in the NCBI database (A) by lacking the 35-bp exon 3 and that mSmarca2-b3 retains the 
54-bp exon 5 that is absent in the mSmarca2-b2. The exon 1 of mSmarca2-b10 retains 408 bp of intron 1. 
Alternative splicing of mouse Smarca2-b 
Wondering  whether  the  short  transcript 
mSmarca2-b also undergoes alternative splicing at the 
54-bp  exon,  we  used  a  forward  primer  (mSmar-
ca2’F192;  table  1)  located  at  the  96-bp  exon  2  of 
mSmarca2-b and the same reverse primer used above 
(mSmarca2R4524) to perform PCR with cDNA sam- Journal of Cancer 2011, 2 
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ples  from  H5  and  M8  cells.  The  PCR  products  re-
vealed two bands (Fig. 1D) sometimes but three bands 
(Fig. 1E) at other times in agarose gel. Purifying and 
then sequencing each of the two bands shown in Fig. 
1D revealed that the top band was a variant lacking 
the  35-bp  exon  3  but  retaining  the  54-bp  exon  5, 
whereas the bottom band was a variant lacking both 
exons 3 and 5 (Supplementary Material: Fig. S2). We 
also purified and sequenced each of the three bands 
appearing in Fig. 1E, and found that the top and the 
bottom bands were the above two variants,  respec-
tively,  whereas  the  middle  band  contained  both  of 
these two variants and thus was a heterodimer that 
sometimes occurs between two similar sequences in 
PCR products, according to our experience. We des-
ignated  the  sequence  in  the  NCBI  database 
(NM_026003.2) (Fig. 1A) that contains the 35-bp exon 
3  as  mSmarca2-b2  and  the  two  new  sequences  as 
mSmarca2-b3 and -b4, respectively (Fig. 1F), in case 
there is a full-length variant mSmarca2-b1 that retains 
both exons 3 and 5 as seen in the human (see below). 
Identification of human Smarca2-b and its splicing 
pattern 
Wondering  whether  the  short  transcript,  i.e. 
Smarca2-b,  is  also  expressed  in  humans,  we  per-
formed  RT-PCR  with  the  forward  primer  mSmar-
ca2’F43,  which  is located at  exon  1  of  mSmarca2-b, 
and with the reverse primer mSmarca2R4524 that is 
located at exon 7 of mSmarca2-b (table 1). The PCR 
products from cDNA samples of multiple human cell 
lines or tissues revealed multiple bands in agarose gel. 
Results  from  some  cell  lines  are  presented  in  the 
middle panel of Fig. 2A and 2B, whereas similar data 
from many other cell lines and tissues are not shown.  
We collectively purified these bands and cloned 
them into a TA vector. Cloned cDNA products were 
from RNA samples of MCF15 human breast cancer 
cells (22), AsPC-1 pancreatic cancer cells, and a com-
mercial RNA sample of normal human pancreas. For 
each of these three cell lines and tissue, four to six 
plasmid clones were sequenced and the clones from 
the same cell line or tissue show different sequences 
(table 2). 
The sequence results shows that exon 1 has three 
different 3’ splice sites, two of which result in a dele-
tion of 7-bp or 41-bp at the 3’end, relative to the third 
one (Fig. 2C). Another finding is alternative skip of 
the 96-bp exon 2, the 35-bp exon 3, and/or the 54-bp 
exon 5. A total of nine mRNA variants were identified 
among  the  15  plasmid  clones  sequenced  (table  2), 
designated  as  hSmarca2-b1,  hSmarca2-b2…  hSmar-
ca2-b9,  respectively,  as  illustrated  in  Fig.  2D  (se-
quences in Supplementary Material: Fig. S3). 
The  new  finding  of  the  alternative  skip  of  the 
35-bp exon 3 in mouse Smarca2-b was also observed 
in  the  human.  Actually,  seven  out  of  nine  variants 
identified (b3, b4, b5, b6, b7, b8 and b9 vs b1 and b2 in 
Fig. 2D) or 12 out of 15 plasmid clones sequenced (ta-
ble  2)  skip  this  exon,  suggesting  that  the  variants 
without exon 3 are the majority. Similarly, the vari-
ants  that  skip  the  54-bp  exon  5  are  also  dominant, 
since six out of nine variants identified (b2, b4, b5, b6, 
b7 and b9 vs b1, b3 and b8) or 11 out of 15 plasmid 
clones sequenced (table 2) skip this exon. These fea-
tures  are  even  more  obvious  when  plasmid  clones 
sequenced for other purposes are counted (see below). 
 
Table 2: Summary of the hSmarca2-b variants with alternative splice at exons 1, 2, 3 and/or 5 and the deduced protein 
identified in the normal pancreas as well as MCF15 and AsPC-1 cells. 
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Fig 2: Detection of hSmarca2 mRNA variants. A & B: RT-PCR detection of hSmarca2 in several human breast (A) and pancreatic (B) 
cancer cell lines or non-malignant (MCF10A) cells with the F3855+R4524 primers for hSmarca2-a and the F’43+R4524 primers for 
hSmarca2-b. Note that the hSmarca2-b level is very low but still seems to be visible in MCF7 cells. The separate panel in (A) shows 
that the hSmarca2-b, but not the hSmarca2-a, can still be detected in SKBR3 cells when the amount of cDNA template and the PCR 
cycles were increased. C: Sequence of the longest (134-bp) exon 1 of the hSmarca2-b determined by 5’RACE. Two transcription 
initiation sites are indicated by arrows pointing right. Two additional 3’ splice sites that result in a deletion of 7-bp or 41-bp, 
respectively, are indicated by the arrows pointing up. D: Illustration of the nine hSmarca2-b variants confirmed by DNA sequencing. 
The size of exon 1 is not indicated because it varies, but the skip of 7-bp or 41-bp is indicated by the shaded 3’ end. 
 
Identification of different transcription initiation 
sites of human Smarca2-b 
After confirming the existence of hSmarca2-b, we 
determined its initiation site by performing 5’RACE 
with  RNA  samples  from  L3.6pL  human  pancreatic 
cancer  cells  and  with  hSmarca2R4230  and  hSmar-
ca2R4106  (the  number  was  calculated  based  on 
hSmarca2-a since the initiation site of hSmarca2-b was 
unknown) as the reverse primers that are localized at 
exon 4, which does not undergo alternative splicing 
(Fig.  2D).  Sequencing  five  plasmid  clones  of  the 
5’RACE products identified two initiation sites  that 
were nine nucleotides apart in intron 27 of hSmar-
ca2-a (Fig. 3C). The sequence results also revealed the 
7-bp deletion from the 3’-end of exon 1 and the skip of 
exon 3 identified by the above described TA cloning 
(sequences in Supplementary Material: Fig. S3).  Thus, 
a random combination of the two alternative initiation 
sites and the three 3’ alternative splice sites of exon 1 
might,  theoretically,  result  in  a  longest  exon  1  of 
134-bp and a shortest exon 1 of 84-bp (Fig. 2C). We 
have not yet identified the 84-bp exon 1 but it may 
exist  in  our  5’RACE  products.  Mathematically,  two 
different transcription initiation sites, three different 
3’  alternative  splice  sites  of  exon  1,  and  alternative 
skips of exons 2, 3 and 5 may result in 48 (2x3x2x2x2)  Journal of Cancer 2011, 2 
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different hSmarca2-b variants, although we have only 
identified nine of them. 
Expression of Smarca2-a and Smarca2-b in various 
cell lines 
We  have  determined  the  expression  levels  of 
Smarca2-a  in  many  cell  lines  but  here  we  only  de-
scribe those data that are discrepant from or absent in 
the literature. SKBR3 human breast cancer cells were 
reported to express relatively high level of BRM pro-
teins (12), but we were not able to detect hSmarca2-a 
in this cell line (Fig. 2A). On the other hand, we found 
that the Smarca2-a level in 4T07 mouse breast cancer 
cells (Fig. 1C) and MiaPaca2 human pancreatic cancer 
cells (Fig. 2B) was very low or undetectable. Moreo-
ver, we detected hSmarca2-a in Panc-1 human pan-
creatic cancer cells (Fig. 2B).  
The  short  transcript  Smarca2-b  was  expressed 
abundantly in most mouse and human cell lines and 
tissues. Smarca2-b was still readily detectable in some 
cell lines wherein the level of Smarca2-a was very low 
or undetectable, such as in 4T07 and MiaCapa2 cells 
(Fig. 1C and 2B). In SKBR3 cells, hSmarca2-b could be 
detected  when  the  number  of  PCR  cycles  or  the 
amount of cDNA template was increased, although 
the  hSmarca2-a  was  still  undetectable  (Fig.  2A). 
However,  there  still  were  some  cell  lines  such  as 
HC11, MCF7 and T47D wherein the Smarca2-a level 
was detected abundantly but the level of the Smar-
ca2-b was very low (Fig. 1C and 2A). 
Bioinformatic analyses of ORF of hSmarca2-a and 
hSmarca2-b 
In the NCBI database, hSmarca2-a1 and hSmar-
ca2-a2 encode only a protein of 1590 amino acids (aa) 
and  1572  aa,  respectively.  However,  ORF  analyses 
with DNAStar software identifies a total of 48 ATG 
(AUG in mRNA) translation start codons in hSmar-
ca2-a, each of which encodes an ORF longer than 100 
aa but all the ORFs are in the same frame and end at 
the TGA (UGA in mRNA) translation stop codon at 
the 4872-4875th nucleotides (nt) (table 3). hSmarca2-a2 
has the same 48 ATGs but the stop codon occurs ear-
lier (at the 4818-4820th nt TGA), because of the lack of 
the 54-bp exon 29, which makes the last (the shortest) 
ORF different from their counterparts in hSmarca2-a1 
(table 3). The 48 ORFs in hSmarca2-a1 encode proteins 
that range from 1590 to 119 aa, which, if expressed, 
are estimated at about 181 kD to 13 kD on a western 
blot.  
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Fig 3: Illustration of deduced open reading frame (ORF) of hSmarca2-b mRNA variants. Every other exon is shaded to show the 
length of each exon and the boundary of neighbor exons. The number of exon (E) is indicated at the left margin. There are two 
putative ATG translation start codons, located in exons 2 and 4, respectively. No matter whether exon 1 is initiated from the A1 or 
A2 site (arrows pointing right) or has or not a 7- or 41-bp deletion at its 3’-end, it does not affect ORF. Those variants that lack exon 
2 have only one ORF starting from ATG2 at exon 4 and ending at the only TGA stop codon in exon 10. A: In those variants that lack 
the 35-bp exon 3, the ATG1 and ATG2 are in the same ORF, which ends at the TGA in exon 10 as well. Thus, the proteins starting 
from ATG1 have additional 40 amino acids (aa) at the N-terminus compared with those starting from ATG2, whereas those variants 
retaining the exon 5 have an 18-aa insert (in box). B: In those variants retaining the 35-bp exon 3, ATG1 starts a protein that ends 
at a TGA in exon 4, thus having only 98 aa. The sequence of its first 31 aa encoded by exon 2 is identical to the corresponding part 
of those proteins that are also started from ATG1, whereas the remaining 67 aa constitute a sequence that is different from any 
part of BRM-related proteins, due to the frame-shift caused by the insert of exon 3. Only ATG2 starts the BRM-related proteins. C: 
Illustration of the BRM and related proteins, with the variants that may produce the protein indicated in brackets. The boxes that 
are in the same format and vertically aligned at the same position represent identical sequence, with open box as BRM or BRM 
related sequence and small grey box representing the 18 aa encoded by the 54-bp exon that may be alternatively skipped. The two 
BRM proteins differ by alternative skip of 18 aa. Note that the 294-aa and 276-aa proteins share the first 31 aa (slashed box) with 
the 98-aa peptide but differ from the 254-aa and 236-aa proteins by this 31-aa sequence. The remaining 67 aa (checkered box) of 
the 98-aa peptide does not exist in any other protein.  Journal of Cancer 2011, 2 
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Table 3: Analysis of open reading frame of human hSmarca2-a1 
 
 
 
ORF analysis also shows that those hSmarca2-b 
variants (b3, b4, b6 and b7 shown in Fig. 2D) that lack 
exon 3 may be translated from two ATG translation 
start  codons  located  at  exons  2  and  4,  respectively 
(Fig. 3A). These two ATGs are within the same frame 
that ends at a TGA stop codon in exon 10; the proteins 
starting  from  ATG1  have  additional  40  aa  at  the 
N-terminus compared with those starting from ATG2. 
Alternative skip of the 54-bp exon 5 deletes 18 aa from 
these proteins (Fig. 3A). However, in those variants 
that retain exon 3 (b1 and b2 shown in Fig. 2D), the 
two different ATGs start different ORFs because exon 
3 causes a frame-shift (Fig. 3B). The protein starting 
from ATG1 at exon 2 will end at a TGA in exon 4, 
resulting in a 98-aa short peptide (Fig. 3B). The pro-
teins starting from ATG2 still end at the second TGA 
in exon 10 and may have an alternative deletion of 18 
aa because of the skip of exon 5, just like those pro-
teins from the variants without exon 3. Skip of exon 2 
in certain variants (b5, b8 and b9 in Fig. 2D) also de-
letes  the  ORF  starting  from  ATG1  without  creating 
any new ORF, and thus has only one ORF starting 
from ATG2 (Fig. 3A and 3B). 
The above situations of hSmarca2-b variants, i.e. 
two different ATGs in the absence of exon 3, the first 
ATG in the presence of exon 3 that causes an early 
translation  termination,  and  the  alternative  skip  of 
exon 5, together can result in five different proteins 
(Fig. 3C). Four of the five belong to the BRM family 
and contain 294, 276, 254, and 236 aa, with a calcu-
lated molecular weight of 33731.76, 31733.55, 29490.84 
and 27492.64 Daltons, respectively, much smaller than 
the  BRM  proteins  derived  from  the  hSmarca2-a1 
(181278.65  Daltons)  or  the  hSmarca2-a2  (179280.45 
Daltons). Moreover, the second ATG is in the same 
ORF of hSmarca2-a. Therefore, the 294-aa and 276-aa 
proteins that are translated from the first ATG have 
the same C-terminal sequence as the hSmarca2-a1 and 
hSmarca2-a2 proteins, whereas the 254-aa and 236-aa 
proteins translated from the second ATG are identical 
to  a  C-terminal  part  of  the  hSmarca2-a1  or  hSmar-
ca2-a2  derived  BRM  proteins  (Fig.  3C).  The  98-aa 
short peptide, which is translated from the first ATG 
of the variants containing exon 3 (b1 and b2), is cal-
culated as 11597.91 Daltons. Its first 31-aa sequence 
encoded by exon 2 is identical to the corresponding 
part  of  the  294-aa  and  276-aa  proteins  (Fig.  3C), 
whereas  the  remaining  sequence  of  67  aa  differs 
completely  from  any  part  of  BRM  or  BRM-related 
proteins, due to the frame-shift caused by exon 3. 
Small BRM-immunoreactive proteins on western 
blot 
We performed western blot assay using a mouse 
monoclonal antibody (sc-166579)  and a  rabbit poly-
clonal antibody (sc-28710) that were raised against the 
1531-1586th aa of hSmarca2-a1, a region shared with 
Smarca2-b. Both antibodies identified several  bands 
between 24-35 kD and a band slightly higher than 40 
kD in cell lines of  human and mouse origins.  Data 
from some of the cell lines were shown in Fig. 4. These 
antibodies also recognized several other bands larger 
than 50 kD or smaller than 24 kD (data not shown). 
The  identities  of  these  small  BRM-immunoreactive 
proteins are unclear. The BRM proteins of about 180 
kD fractioned in a much lower percentage (6%) PAGE 
were  detected  only  weakly  (data  not  shown),  in 
strong  contrast  to  the  high  abundance  of  the  much 
smaller proteins shown in Fig. 4. 
Effects of cyclin D1 and serum starvation on 
Smarca2 expression 
 We  had  previously  transformed  NMuMG 
mouse  mammary  epithelial  cells  with  a 
pcDNA3.1neo-cyclin  D1  (D1)  construct  and  estab-
lished the D1 expressing, malignant ND5 and ND11 
clones (19). ND5 and ND11 cells showed a dramatic  Journal of Cancer 2011, 2 
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decrease  in  the  levels  of  both  mSmarca2-a  and 
mSmarca2-b,  compared  with  the  parental  NMuMG 
non-malignant cells (Fig. 5A). Smarca2-b was still de-
tectable in ND11 clone, but its splicing was changed 
as evidenced by different patterns of bands on aga-
rose gel between ND11 and NMuMG cells (Fig. 5A). 
Interestingly, ND11 cells showed an additional band 
at  a  higher  molecular  weight  (arrow  in  Fig.  5A). 
Cloning  this  band  to  a  TA  vector  followed  by  se-
quencing some plasmids revealed that it was an al-
ternative splice variant that retained 408 bp of intron 1 
at the 3’ end of exon 1 (Supplementary Material: Fig. 
S2). This variant, which lacks exons 3 and 5 as well, 
was also expressed at a low abundance in some other 
mouse cancer cell lines (data not shown). We name 
this variant “mSmarca2-b10” in case similar retention 
of intron 1 may later be identified in human Smar-
ca2-b, although not yet by now. 
 
Fig 4: Western blot assays show that a rabbit (left panel) and a 
mouse (right panel) BRM C-terminal antibodies recognize sev-
eral proteins in the lysates from a mouse (4T1) and several 
human cancer cell lines. Note that several proteins between 
24-35 kD are recognized by both antibodies, in addition to a 
protein slightly higher than 40-kD. The same membrane was 
stripped  and  re-blotted  with  β-actin  to  show  the  protein 
loading, although no attempt is made to compare the expres-
sion levels among the four unrelated cell lines. 
 
Fig 5: Effect of cyclin D1 (D1) and serum starvation on Smarca2 expression. A: Two malignant clones (ND5 and ND11) of NMuMG cells 
transformed by stable expression of a pcDNA3.1-D1 construct show dramatic decreases in the levels of mSmarca2-a and mSmar-
ca2-b detected by RT-PCR, compared with the parental NMuMG cells. ND11 cells also manifest a changed pattern of different 
mSmarca2-b variants and express a variant at a high molecular weight (arrow). B: Comparison of the MCF7 cells infected with a 
retrovirus containing a Flag-D1 construct (D1), a Flag-K112E mutant (KE) or the empty vector (V) shows that D1 dramatically 
decreases the level of hSmarca2-a but the KE mutant attenuates this effect of D1. C, D and E: Effect of serum starvation and 
retroviral infection with D1 or its K112E mutant on the levels of hSmarca2-a and hSmarca2-b, detected by RT-PCR, in MDA-MB231 
(C), L3.6pL (D) and AsPC-1 (E) cells. F: Illustration of how serum and D1 regulate the expression and splicing of Smarca2-a and 
Smarca2-b. Serum derived growth stimuli utilize some transcription factors (TFx) to activate or repress the promoter region (grey 
box) and the intron 27 (that is also the promoter of Smarca2-b) of the Smarca2 gene (black box). D1, which also acts as a down-
stream effector of serum, binds to some other transcription factors (TFy) to activate or repress these promoter regions, but 
whether CDK4 or CDK6 is involved is unclear. The pre-mRNA of Smarca2-a is spliced alternatively to the -a1 or -a2 variants while the 
Smarca2-b pre-mRNA to -b1, -b2… or -b9. These splicing processes may be regulated by serum via D1 or via other splice factors. The 
effect of D1 on splicing is more evident in a chronic situation as seen in D1 transformed ND11 clone of NMuMG cells, but whether 
CDK4 or CDK6 is involved remains elusive.  Journal of Cancer 2011, 2 
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As shown in Fig. 5B, ectopic expression of D1 
decreased the Smarca2-a level in MCF7 cells while the 
Smarca2-b level remained undetectably low under the 
same  condition  as  seen  in  the  vector  infected  cells. 
One  major  function  of  D1  is  to  activate  Cyclin  De-
pendent Kinase-4 (CDK4) or -6 (CDK6), but a single 
nucleotide  mutation  of  D1  that  changes  the  112th 
amino acid (K112E) abolishes its activity to activate 
these CDKs (23). Interestingly, infection of MCF7 cells 
with a retroviral K112E mutant had only a mild effect 
on hSmarca2-a (Fig. 5B), indicating that down regula-
tion of hSmarca2-a by D1 largely depends on its acti-
vation  of  CDK4  or  CDK6.  In  MDA-MB231  human 
breast cancer cells, however, D1 decreased Smarca2-b 
while affecting Smarca2-a only mildly, if at all, when 
the  cells  were  cultured  with  10%  serum  (Fig.  5C). 
K112E  mutation  also  decreased  the  effect  on  Smar-
ca2-b,  again suggesting its  dependence  of  CDK4  or 
CDK6 (Fig. 5C). 
Like in MDA-MB231 cells, ectopic D1 in L3.6pL 
cells significantly down regulated Smarca2-b without 
affecting  Smarca2-a  (Fig.  5D).  However,  in  AsPC-1 
human  pancreatic  cancer  cells,  ectopic  D1  slightly 
induced  Smarca2-b  without  significantly  affecting 
Smarca2-a  when  the  cells  were  cultured  with  10% 
serum (Fig. 5E). 
Deprival  of  MDA-MB231  cells  from  serum  in 
culture for 48 hours dramatically decreased the level 
of Smarca2-b without affecting Smarca2-a (Fig. 5C). 
However, serum starvation together with ectopic D1, 
but not its K112E mutant, could significantly decrease 
the Smarca2-a level when compared with the empty 
vector expressing counterparts, while the Smarca2-b 
level remained inhibited by serum starvation in D1 or 
K112E expressing MDA-MB231 cells (Fig. 5C). L3.6pL 
cells showed a similar decrease in Smarca2-b, but not 
in  Smarca2-a,  in  response  to  serum  starvation  (Fig. 
5D).  However,  unlike  in  MDA-MB231  cells,  serum 
starvation with a concomitant D1 expression was still 
unable to significantly change the level of Smarca2-a 
in L3.6pL cells (Fig. 5D). In opposite to MDA-MB231 
and L3.6pL, AsPC-1 cells showed a significant induc-
tion of both Smarca2-a and Smarca2-b in response to 
serum starvation (Fig. 5E). Interestingly, D1 expres-
sion attenuated the induction of Smarca2-a by serum 
starvation, although D1 alone was not able to signifi-
cantly inhibit Smarca2-a in the presence of 10% serum 
(Fig. 5E). D1 did not seem to markedly affect Smar-
ca2-b in AsPC-1 cells wherein Smarca2-b seems to be 
more abundantly expressed than Smarca2-a. 
Discussion 
Splicing of mSmarca2-a and expression of hSmar-
car2-b 
The first new finding of our study is that the long 
transcript in the mouse (mSmarca2-a) also undergoes 
alternative splicing at the 54-bp exon 29 to produce 
the -a1 and -a2 variants as seen in the human whereas 
the  human  Smarca2  gene  also  expresses  the  short 
transcript, i.e. hSmarca2-b, just like its mouse coun-
terpart. Actually, we identified two transcription ini-
tiation  sites  for  hSmarca2-b  in  the  intron  27  of  the 
gene. Another novel finding is that hSmarca2-b can be 
alternatively spliced at three different 3’ sites of exon 1 
and at exons 2, 3 and 5. These complex patterns of 
alternative  splicing,  together  with  alternative  tran-
scription  initiations,  may  produce  48  different 
hSmarca2-b mRNA variants, although we have only 
confirmed  nine  of  them.  Thus,  in  both  human  and 
mouse,  the  Smarca2  gene  is  expressed  to  a  long 
(Smarca2-a) and a short (Smarca2-b) transcripts; both 
transcripts undergo alternative splicing, especially the 
short one. 
Ratios within or among Smarca2-a and Smarca2-b 
variants 
Of  the  two  Smarca2-a  variants  in  both  mouse 
and human, Smarca2-a2 that lacks the exon 29 is ex-
pressed  at  a  higher  amount  in  most  human  and 
mouse cell lines we studied, relative to Smarca2-a1, 
since  the  bottom  band  of  the  Smarca2-a  duplex  in 
agarose gel is dominant in most cases (Fig. 1B, 1C, 2A 
and 2B). Skip of this 54-bp exon seems to be prevailing 
among Smarca2-b variants as well. Therefore, we in-
tend to consider that this exon appears only as a vari-
ation whereas the wild type forms of the long and 
short mRNAs do not contain this exon. Under what 
condition this exon appears is intriguing but remains 
to be determined. 
One of the surprising findings is that Smarca2-b 
is detected more abundantly than Smarca2-a in many 
cell lines, suggesting that the short transcript may be 
expressed at a higher level in many cases. Therefore, it 
may be Smarca2-b, not the much better studied BRM 
proteins  translated from Smarca2-a,  that  better  rep-
resents the function of the Smarca2 gene. Of the many 
cell lines studied, MCF7 and T47D breast cancer cells 
and HC11 mammary epithelial cells are exceptions, as 
they show the opposite, i.e. a high level of Smarca2-a 
but a low level of Smarca2-b. Why these exceptions 
only occur to cell lines derived from mammary epi-
thelium is unclear, probably just fortuitous.  
Decristofaro  et  al  report  that  Panc-1  cells  are 
negative for BRM protein (12) whereas Rosson et al 
detect relatively high levels of Smarca2-a mRNA and 
BRM protein in this cell line (15). Like Rosson et al, we 
detect Smarca2-a mRNA in Panc-1 cells as well. On 
the other hand, we cannot detect Smarca2-a in SKBR3  Journal of Cancer 2011, 2 
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cells although DeCristorfard et al detect BRM protein 
in this cell line (12). Silencing of the Smarca2 gene is 
generally considered to be due to epigenetic mecha-
nisms (26-28). The same cell lines in different investi-
gators’ laboratory may differ in the degree of epige-
netic silencing, since epigenetic control such as his-
tone deacetylation can be changed readily. This may 
be a reason for the discrepant data on the expression 
status of Smarca2 in Panc-1 and SKBR3 cells observed 
by  different  investigators.  If  so,  we  may  be  able  to 
control  the  behaviors  of  cancer  cells  by  regulating 
epigenetic  control  of  the  Smarca2  gene,  which  may 
have a potential in clinical use eventually. 
Complex ORFs encoded by various Smarca2-b var-
iants 
The complexity of human Smarca2-b occurs not 
only at the mRNA level but probably also at the pro-
tein level, because our bioinformatic analysis identi-
fies two first ATG translation start codons that may or 
may not be in the same ORF, depending on whether 
the variants contain the 35-bp exon 3. Moreover, al-
ternative skip of the 54-bp exon 5 also results in an 
in-frame deletion of 18 aa. These ORFs encode four 
different BRM-related proteins with 294, 276, 254 or 
236 aa, respectively, in addition to a 98-aa short pep-
tide.  In  the mouse,  mSmarca2-b3  and  mSmarca2-b4 
encode  a  294-aa  and  a  276-aa  protein,  respectively, 
whereas the mSmarca2-b10 may utilize another ATG 
at the end of exon 1, which adds two more amino ac-
ids to the N-terminus of mSmarca2-b4, thus produc-
ing a 278-aa protein. 
The 98-aa peptide encoded by hSmarca2-b1 and 
-b2 that contain the 35-bp exon 3 is of interest, if it is 
really expressed. Because the sequence of its first 31 aa 
is identical to the corresponding part of the 294-aa and 
276-aa  proteins  (Fig.  3C),  it  may  be  considered  a 
member of the BRM family. However, this 31-aa se-
quence does not exist in BRM or in the 254-aa and 
236-aa proteins, and the remaining sequence of 67 aa 
also differs completely from any part of BRM or BRM 
related  proteins.  Therefore,  the  nature  of  this  98-aa 
peptide is uncertain. It needs to be pointed out that 
the  only  Smarca2-b  mRNA  (NM_026002.2)  docu-
mented  in  the  NCBI  database  is  a  mouse  sequence 
that contains the 35-bp exon 3, and its ORF starts from 
ATG1 in exon 2 and stops earlier, encoding only 72 aa, 
not 98 aa. The NCBI database shows only the 236-aa 
protein (NP-080279.1) without documenting this 72-aa 
peptide, probably because it is too short. It also needs 
to be mentioned that the variants which contain the 
35-bp exon 3 occur only as relatively rare events in 
both human and mouse in our study. Therefore, the 
NM_026002.2  sequence  in  the  NCBI  database  is 
somewhat  misleading  as  it  does  not  represent  the 
majority. In other words, this 35-bp exon should be 
considered as an extra one that appears only in minor 
variants, not in the wild type forms, of hSmarca2-b. 
The 254-aa and 236-aa proteins are encoded by 
the variants that lack exon 2 (b5, b8 and b9) or the 
variants containing exon 3 (b1 and b2). The possible 
existence of these proteins somewhat puzzles us be-
cause the 254-aa or 236-aa sequence is part of the BRM 
protein  translated  from  Smarca2-a1  or  Smarca2-a2, 
respectively, as illustrated in Fig. 3C. One of the pos-
sibilities is that cells may sometimes prefer a simpli-
fied or specified function by the C-terminal  part of 
BRM proteins over the more complex functions by the 
full-length BRM. The 294-aa and 276-aa proteins en-
coded  by  the  variants  lacking  exon  3  but  retaining 
exon 2 (b3, b4, b6 and b7) contain the 31-aa sequence 
at the N-terminus that does not exist in BRM, thus 
sharing some functions with BRM on one hand and 
with the 98-aa peptide on the other. Therefore, these 
proteins may be a special group of the BRM family 
and their existence may be meaningful. 
Mechanisms for the appearance of small BRM im-
munoreactive proteins 
Using two BRM C-terminal antibodies, we show 
for the first time western blot data of multiple proteins 
of 24-35 kD, which may be 1) degraded or proteolyzed 
products of the 180-kD BRM proteins, 2) proteins that 
are irrelevant to Smarca2 but immunoreactive to the 
BRM C-terminal antibodies, i.e. nonspecific bands on 
the blot, 3) Smarca2-b proteins as they are within the 
estimated molecular weights, or 4) Smarca2-a proteins 
translated from some of the 48 in-frame ATGs (AUG 
is referred to as ATG herein to abide to NCBI database 
that presents mRNA as DNA sequence, including the 
Smarca2 mRNA variants). The first possibility is less 
likely because the 180-kD BRM proteins are detected 
much less abundantly compared with the 24-35 kD 
proteins and western blots of β-actin and other pro-
teins (data now shown) confirm the high quality of 
the protein preparation without obvious degradation. 
The  second  or  third  possibility  needs  to  be  deter-
mined by more studies. If Smarca2-b proteins exist, 
each Smarca2-b mRNA variant needs to be causally 
linked to one or several specific bands on the western 
blot. Cloning the full-length cDNA of various Smar-
ca2-b variants that encode different ORFs and raising 
the corresponding antibodies are prerequisites for this 
line of work, which are tedious and thus beyond this 
communication. The fourth possibility is of interest as 
this  type  of  situation  is  rarely  discussed.  Generally 
speaking, some of the in-frame ATGs in many genes, 
like  the  48  in-frame  ATGs  of  hSmarca2-a,  may  be  Journal of Cancer 2011, 2 
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functional via a non-classical cap-dependent or even 
cap-independent  mechanism  of  protein  translation, 
including leaky scanning, reinitiation, and IRES (in-
ternal ribosome entry site) (29-31). In the case of IRES, 
whether an in-frame ATG is functional depends in a 
large part on ITAFs (IRES trans-acting factor) expres-
sion of which varies among different cells or cellular 
situations (32,33). For instance, an IRES existing in the 
exon 1 of the c-myc oncogene is 20-fold more active in 
Hela cells than in MCF7 cells (34). In silico analyses 
suggest that up to 10% of cellular genes contain IRES 
(33), although it remains to be determined whether 
Smarca2 mRNAs encompass an IRES. Besides IRES, 
some relative upstream ATGs may be used as “up-
stream ATGs” to control translation from the ATGs at 
their downstream via a leaky scanning or reinitiation 
mechanism  (30,31).  By  using  these  non-classical 
cap-dependent  or  even  cap-independent  translation 
mechanisms,  cells  can  regulate  mRNA  decay  or 
translation efficiency or can produce different protein 
isoforms  that  differ  in  the  N-terminus  and  thus  in 
some functions (29-31,35).  
Regulation of Smarca2 expression by D1 and serum 
Few  factors  have  been  identified  that  regulate 
the expression of Smarca2, especially the Smarca2-b. 
Serum starvation inhibits cell growth while D1 accel-
erates it, both via the pRb-E2F pathway. Moreover, D1 
is known to act as a sensor of cells to deliver extra-
cellular growth signals, such as those derived from 
serum, to the cell cycle machinery (Fig. 5F) (36,37). For 
these  reasons,  we  originally  anticipated  that  serum 
starvation should induce Smarca2 whereas D1 should 
inhibit it, since BRM is considered to inhibit cell pro-
liferation  by  mediating  the  pRb-E2F  pathway  (8,9). 
We  indeed  observe  an  induction  of  hSmarca2-a  by 
serum starvation in AsPC-1 cells and an inhibition of 
hSmarca2-a by D1 in MCF7 cells as anticipated. Un-
expectedly,  however,  serum  starvation  does  not  in-
duce  hSmarca2-a  in  MDA-MB231  and  L3.6pL  cells 
whereas  D1  alone  does  not  inhibit  it  in  AsPC-1, 
MDA-MB231  and  L3.6pL  cells.  More  surprisingly, 
although serum starvation significantly changes the 
levels of Smarca2-b in all three cell lines studied (Fig. 
5C, 5D and 5E), these cell lines actually respond quite 
differently and even oppositely. Obviously, the short 
transcript is more sensitive to serum-derived factors 
and thus may be a more important regulator than the 
Smarca2-a for cell cycle progression, which may be 
why  Smarca2-b  is  more  abundantly  expressed  than 
Smarca2-a in many cell lines. Nevertheless, these un-
expected  results  suggest  a  complex  regulation  of 
Smarca2 by serum and D1 and the complexity may 
occur at two levels: 1) There may be many genes other 
than D1 that also act as downstream effectors of se-
rum-derived factors to control cell growth by regula-
tion of Smarca2 and these genes show different pat-
terns of changes in different cell lines. 2) D1 per se uti-
lizes  multiple  mechanisms  to  regulate  Smarca2  ex-
pression and splicing (Fig. 5F). As reviewed by two of 
us  recently  (36,37),  D1  functions  via  three  different 
mechanisms,  i.e.  a)  binding  to  CDK4/6  to  form  a 
holoenzyme to phosphorylate pRb or other substrates, 
b) forming a complex with CDK4/6 without involv-
ing  their  kinase  activity,  or  c)  acting  via  a 
CDK4/6-independent mechanism. The third mode of 
action has so far been observed only in regulation of 
genes’ transcription, which is achieved by binding of 
D1  to some transcriptional factors (Fig. 5F) such as 
steroid hormone receptors. Few, if any, of these tran-
scriptional  regulations  involve  CDK4/6,  to  our 
knowledge. For this reason, it is surprising that the 
K112E mutant that cannot activate CDK4/6 is not as 
effective  as  the  wild  type  D1  in  regulation  of 
Smarac2-a and Smarca2-b mRNA levels, as it implies 
the  involvement  of  these  CDKs.  More  studies  are 
needed to further determine whether the effects of D1 
on the expression of Smarca2-a or Smarca2-b occur at 
the transcriptional level. 
Although  the  above  discussed  short-term  or 
temporary  effects  of  D1  on  Smarca2  expression  are 
somewhat less evident and different among the ret-
rovirus  infected  MCF7,  MDA-MB231,  L3.6pL  and 
AsPC-1  cells,  two  clones  (ND5  and  ND11)  of  D1 
transformed NMuMG cells consistently show that the 
chronic effects of D1 are dramatic decreases in both 
Smarca2-a  and  Smarca2-b  expression  or  altered 
splicing pattern of Smarca2-b. Whether and how D1 
plays a role in RNA splicing is an interesting question 
that has rarely been studied (Fig. 5F), but it has been 
reported  that  D1  regulates  splicing  of  fibroblast 
growth factor 1 receptor (38) and D1b, a splice variant 
of  D1,  utilizes  a  critical  splice  factor  ASF/SF2  as  a 
downstream effector to regulate splicing (39). These 
chronic effects seen in ND5 and ND11 cells are likely 
to  be  indirect  events  mediated  by  other  genes,  alt-
hough whether CDK4 or CDK6 is involved remains 
elusive (Fig. 5F). Nevertheless, these effects not only 
dovetail with the notion that the Smarca2-a products 
BRM proteins are tumor suppressors but also further 
suggest  that  some  of  the  Smarca2-b  splice  variants 
may be tumor suppressive as well.  
Conclusions 
In  summary,  mSmarca2-a  also  engenders  two 
alternative splice  variants  with  or  without  exon  29, 
just  like  hSmarca2-a,  whereas  the  hSmarca2  gene 
produces the short transcript hSmarca2-b as well, just  Journal of Cancer 2011, 2 
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like its mouse counterpart. Nine hSmarca2-b mRNA 
variants  are  identified  and  many  more  anticipated, 
due to two alternative initiation sites as well as alter-
native splicing at three different 3’ splice sites of exon 
1 and at exons 2, 3 and 5. mSmarca2-b also undergoes 
alternative splicing at exon 3 and/or exon 5, besides a 
retention of part of intron 1 by exon 1. Some of the 
hSmarca2-b mRNA variants may encode two differ-
ent ORFs, which together may produce five different 
proteins. The expression of Smarca2-a and Smarca2-b 
may be regulated by serum concentration and by D1 
in  a  complex  manner,  and  Smarca2-b  is  expressed 
more abundantly than Smarca2-a in many cell lines. 
These  complex  patterns  of  transcription  initiation, 
expression regulation, and alternative splicing collec-
tively suggest that in some situations the functions of 
the  Smarca2  gene  may  be  very  complex,  not  just 
simply  inhibiting  cell  proliferation  or  tumor  for-
mation, and be exerted mainly by expressing the short 
transcript Smarca2-b. 
Supplementary Material 
Fig. S1: Sequence of the region between exon 26 and 
exon 31 of the mSmarca2-a1 cDNA. Fig. S2: Part of the 
sequences of the three novel mSmarca2-b variants. 
Fig. S3: Sequences of the nine hSmarca2-b variants 
and two of the original 5’RACE sequences.  
http://www.jcancer.org/v02p0386s1.pdf 
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